Finance

Beta
Lists
Equity sectors
Symbols
Symbols
Price
Change
% Change
Trend
Prev Close
Open
High
Low
Volume
Mkt Cap
SIXB
Materials
SIXB
Materials
SIXB
-1,40%
1 076,20
-15,31
-1,40%
—1 091,511 090,401 090,401 074,65——
SIXC
Communications
SIXC
Communications
SIXC
-0,38%
607,80
-2,31
-0,38%
—610,11610,11610,29606,17——
SIXE
Energy
SIXE
Energy
SIXE
+0,67%
1 246,23
+8,25
+0,67%
—1 237,981 237,831 252,411 225,03——
SIXI
Industrials
SIXI
Industrials
SIXI
-1,07%
1 726,08
-18,63
-1,07%
—1 744,711 740,951 747,291 721,57——
SIXM
Financials
SIXM
Financials
SIXM
-0,54%
636,70
-3,48
-0,54%
—640,18639,92643,19634,73——
SIXR
Staples
SIXR
Staples
SIXR
-1,03%
840,87
-8,71
-1,03%
—849,58845,27851,68839,47——
SIXRE
Real estate
SIXRE
Real estate
SIXRE
-0,79%
215,77
-1,71
-0,79%
—217,48217,48218,16215,51——
SIXT
Technology
SIXT
Technology
SIXT
+0,19%
3 266,94
+6,25
+0,19%
—3 260,693 273,363 287,813 240,78——
SIXU
Utilities
SIXU
Utilities
SIXU
-0,54%
937,32
-5,13
-0,54%
—942,45939,39948,80933,98——
SIXV
Health care
SIXV
Health care
SIXV
-0,24%
1 463,27
-3,53
-0,24%
—1 466,801 464,701 467,191 458,36——
SIXY
Discretionary
SIXY
Discretionary
SIXY
-0,67%
2 381,46
-16,04
-0,67%
—2 397,502 395,032 412,012 370,64——
4528:TYO
Ono Pharmaceutical Co Ltd
2 315,50 JP¥
+0,41%
(+9,50) 1D
1 մյս, 15:30:00 GMT+9  ·   JPY
All symbols
SymbolPriceChange% Change
Generating top insights for 4528...
Open
2 287 JP¥
High
2 328 JP¥
Low
2 268 JP¥
Mkt. cap
1,15 տրլն
Avg. vol.
1,79 մլն
Volume
1,50 մլն
Dividend
3,45%
Quarterly dividend
20 JP¥
Ex dividend date
29 սեպ, 2025 թ.
P/E ratio
17,44
52-wk high
2 674 JP¥
52-wk low
1 474 JP¥
EPS
133 JP¥
Shares outstanding
514,12 մլն
No. of employees
4 հզր
News stories
From sources across the web
Profile
Ono Pharmaceutical Co., Ltd. is one of the largest pharmaceutical companies in Japan. It is headquartered in Chuo-ku, Osaka, Japan, with its major plants in Higashinari-ku, Osaka, and Fujinomiya, Shizuoka., and its central research institute at Minase, Shimamoto-cho, Mishima District, Osaka. Ono Pharmaceutical's roots go back to 1717 when Ichibei Ono started his dealer business of pharmaceuticals in Osaka. His business expanded and changed its name a few times, and became Ono Pharmaceutical Industrial Co., Ltd. in 1948. Ono has been listed in Tokyo Stock Exchange since 1963. Its consolidated earnings in the half year ending in March 2018 were 16 billion Japanese yen. Nivolumab, the cancer drug based on the research of Prof. Dr. Tasuku Honjo of Kyoto University, who received the Nobel Prize later in 2018, is marketed by both Ono Pharmaceutical and Bristol-Myers Squibb. In 2024, Harvard University and Ono Pharmaceutical entered into a joint research and drug development agreement. Under it, promising projects to test therapeutic targets will be selected over 5 years under the guidance of Harvard's Office of Technology Development, and ONO will fund the work. Wikipedia
About Ono Pharmaceutical Co Ltd
CEOGyo Sagara | Gyo Sagara
Employees4,29 հզր
Founded1717
HeadquartersՕսակա, Osaka, Ճապոնիա
Sector-
Websiteono-pharma.com
Last report
01 փտվ, 2026 թ.
Fiscal Period
Q3 2026
Normalized EPS / Estimate
-/ -JPY
Revenue / Estimate
139,90 մլրդ/ (129,40 մլրդ est.)JPY
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glanceInsights from the latest news and reports
Previous reportsAll values in JPY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in JPY
2025 թ. մրտ
2025 թ. հնս
2025 թ. սեպ
2025 թ. դեկ
Revenue
112,31 մլրդ
127,54 մլրդ
129,60 մլրդ
139,90 մլրդ
Cost of goods sold
45,24 մլրդ
37,01 մլրդ
34,96 մլրդ
36,68 մլրդ
Cost of revenue
45,24 մլրդ
37,01 մլրդ
34,96 մլրդ
36,68 մլրդ
Research and development expenses
46,30 մլրդ
36,25 մլրդ
34,77 մլրդ
33,53 մլրդ
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
31,86 մլրդ
31,09 մլրդ
30,08 մլրդ
31,73 մլրդ
Operating expense
82,93 մլրդ
68,53 մլրդ
64,56 մլրդ
67,00 մլրդ
Total operating expenses
128,16 մլրդ
105,54 մլրդ
99,53 մլրդ
103,68 մլրդ
Operating income
-15,85 մլրդ
22,00 մլրդ
30,07 մլրդ
36,22 մլրդ
Other non operating income
21,00 մլն
-
-
-
EBT including unusual items
-12,71 մլրդ
22,65 մլրդ
29,52 մլրդ
37,20 մլրդ
EBT excluding unusual items
-15,67 մլրդ
22,65 մլրդ
29,52 մլրդ
37,20 մլրդ
Income tax expense
-6,34 մլրդ
5,02 մլրդ
7,17 մլրդ
8,31 մլրդ
Effective tax rate
49,90%
22,16%
24,30%
22,35%
Other operating expenses
1,31 մլրդ
1,19 մլրդ
-291,00 մլն
1,73 մլրդ
Net income
-6,54 մլրդ
17,67 մլրդ
22,42 մլրդ
28,86 մլրդ
Net profit margin
-5,83%
13,86%
17,30%
20,63%
Earnings per share
-
-
-
-
Interest and investment income
1,90 մլրդ
1,43 մլրդ
677,00 մլն
1,39 մլրդ
Interest expense
-
-773,00 մլն
-1,23 մլրդ
-408,00 մլն
Net interest expenses
1,90 մլրդ
655,00 մլն
-549,00 մլն
979,00 մլն
Depreciation and amortization charges
3,45 մլրդ
-
-
-
EBITDA
-7,13 մլրդ
31,23 մլրդ
39,39 մլրդ
45,82 մլրդ
Gain or loss from assets sale
7,98 մլրդ
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

My tasks
You haven't created a task yet
Your tasks will appear here. Schedule tasks and put Google Finance to work while you're away.
Templates
Watchlist briefing
A daily pre-market analysis of your watchlist
Upcoming Earnings
Upcoming earnings reports in the week
Abnormal Volatility & Volume
Volatility and volume early warning today
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer